Clinical research published in EURETINA’S journal, Ophthalmologica, has reported that treatment of diabetic macular edema with intravitreal bevacizumab and triamcinoclone combined or triamcinoclone only, showed better visual acuity and reduced central macular thickness at 6 weeks and 3 months, compared with bevacizumabl alone (p = 0.041, p = 0.02 at 6 weeks; p = 0.045, p = 0.043 at 3 months, respectively). The study, conducted at the Chuncheon Sacred Heart Hospital, Republic of Korea evaluated 111 eyes in 105 patients with diabetic macular edema and monitored clinical response by BCVA assessment and OCT analysis. The authors concluded that while bevacizumab/triamcinoclone and triamcinoclone alone showed pronounced effects early in the regimen, levels of BCVA or central macular thickness after 1 year appeared comparable in the bevacizumab/triamcinoclone, triamcinoclone alone and bevacizumab alone study groups.